XML 82 R61.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaboration and License Agreements (Details) € in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2015 USD ($) | Oct. 31, 2014 USD ($) | Oct. 31, 2014 EUR (€) | Jul. 31, 2005 USD ($) | Dec. 31, 2015 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions |  |  |  |  |
Sanofi Upfront Payment | $ 300,000,000 |  |  |  |
Sanofi Development and Regulatory Milestone Payments | 430,000,000 |  |  |  |
Sanofi Sales Milestone Payments | 990,000,000 |  |  |  |
Sanofi Development Costs Funded by Lexicon Maximum Amount | 100,000,000 |  |  |  |
Sanofi Revenue Allocated to License Deliverable | 126,800,000 |  |  |  |
Sanofi Revenue Allocated to Development Deliverable | 113,800,000 |  |  |  |
Sanofi Revenue Allocated to Funding Deliverable | $ 59,400,000 |  |  |  |
Sanofi Revenue Recognized |  |  |  |  | $ 126,800,000
Ipsen Total Upfront Payments |  | $ 24,500,000 |  |  |
Ipsen Revenue Allocated to License Deliverable |  | 21,200,000 |  |  |
Ipsen Maximum Regulatory And Commercial Milestones |  | 34,000,000 |  |  |
Ipsen Revenue Allocated to Development Deliverable |  | 1,700,000 |  |  |
Ipsen Revenue Allocated to Committee Deliverable |  | $ 100,000 |  |  |
Ipsen Revenue Recognized |  |  |  |  | 21,400,000
Ipsen Maximum Sales Milestones | € |  |  | € 72 |  |
TX Enterprise Fund Award |  |  |  | $ 35,000,000 |
TX Enterprise Fund Award to Texas AM University System |  |  |  | $ 15,000,000 |
TIGM Per Job Payment Amount |  |  |  |  | 2,415
TIGM Maximum Exposure |  |  |  |  | 14,200,000
TIGM Maximum Exposure Through Reporting Date |  |  |  |  | $ 6,400,000

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumRegulatoryAndCommercialMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumSalesMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoLicenseDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_IpsenRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenTotalUpfrontPayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs. + References No definition available. + Details
Name: | lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential development and regulatory milestone payments under the agreement. + References No definition available. + Details
Name: | lxrx_SanofiDevelopmentandRegulatoryMilestonePayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoFundingDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoLicenseDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_SanofiRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement. + References No definition available. + Details
Name: | lxrx_SanofiSalesMilestonePayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement. + References No definition available. + Details
Name: | lxrx_SanofiUpfrontPayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits. This is the amount through the specified reporting date. + References No definition available. + Details
Name: | lxrx_TIGMMaximumExposureThroughReportingDate
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits. + References No definition available. + Details
Name: | lxrx_TigmMaximumExposure
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Under the terms of the Texas Enterprise Fund award, subject to certain credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay $2,415 for each job Lexicon falls short. + References No definition available. + Details
Name: | lxrx_TigmPerJobPaymentAmount
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition In July 2005, Lexicon received a $35.0 million award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine using Lexicon's proprietary gene trappying technology, which Lexicon completed in 2007. + References No definition available. + Details
Name: | lxrx_TxEnterpriseFundAward
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In July 2005, the Texas Enterprise Fund awarded $15.0 million to the Texas A&M University System for the creation of facilities and infrastructure to house the library. + References No definition available. + Details
Name: | lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration